WCN26-2925 SGLT- 2I: “CAN BE A HOPE FOR PERITONEAL DIALYSIS PATIENTS”

Read full text Summarise with VIRAT
Authors: Kush Dev Singh Jarial, Sukhwinder Singh Sangha, Raj Kumar Kumar, Samriti Gupta, Asheesh Kumar
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Sodium-glucose transporter-2 inhibitors (SGLT-2i) showed promising results in slowing the progression of chronic kidney disease. The DAPA-CKD and EMPA-KIDNEY trials have provided evidence that SGLT-2i can reduce the risk of kidney failure and cardiovascular events. There are various studies in which SGLT-2i has been used in peritoneal dialysis patients but with limited followup period.

Fields of Study & Subjects

Dialysis and Renal Disease Management Chronic Kidney Disease and Diabetes Diabetes Treatment and Management

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105862–105862
Publication date
25 March 2026
Language
EN